Immuno oncology combination therapy with il-2 conjugates and anti-egfr antibodies
AssigneeSynthorx, Inc.
InventorsGiovanni ABBADESSA, Carolina E. CAFFARO, Joseph LEVEQUE, Marcos MILLA, Jerod PTACIN, Timothy R. WAGENAAR
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for treating a cancer in a subject in need thereof, comprising administering IL-2 conjugates in combination with an anti-EGFR antibody.
Claims34
A method of treating a cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of (a) an IL-2 conjugate, and (b) an anti-EGFR antibody, wherein the IL-2 conjugate comprises the amino acid sequence of SEQ ID NO:
- 3 in which at least one amino acid residue in the IL-2 conjugate is replaced by the structure of Formula (I):
- wherein:
- Z is CH2 and Y is
- Y is CH2 and Z is
- Z is CH2 and Y is
- or
- Y is CH2 and Z is
- W is a PEG group having a molecular weight of about 5 kDa, 10 kDa, 15 kDa, 20 kDa, 25 kDa, 30 kDa, 35 kDa, 40 kDa, 45 kDa, 50 kDa, or 60 kDa;
- q is 1, 2, or 3;
- and
- X is an L-amino acid having the structure:
- X−1 indicates the point of attachment to the preceding amino acid residue;
- and
- X+1 indicates the point of attachment to the following amino acid residue;
- wherein the position of the structure of Formula (I) in the amino acid sequence of the IL-2 conjugate is selected from K34, F41, F43, K42, E61, P64, R37, T40, E67, Y44, V68, and L71.
(canceled)
(canceled)
A method of treating a cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of (a) an IL-2 conjugate, and (b) cetuximab, wherein the IL-2 conjugate comprises the amino acid sequence of SEQ ID NO:
- 50, wherein [AzK_L1_PEG30 kD] has the structure of Formula (XII) or Formula (XIII), or is a mixture of the structures of Formula (XII) and Formula (XIII):
- wherein:
- n is an integer such that —(OCH2CH2)n—OCH3 has a molecular weight of about 30 kDa;
- q is 2;
- and
- the wavy lines indicate covalent bonds to amino acid residues within SEQ ID NO:
- 50 that are not replaced.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.